A 4,500‑line spreadsheet and hundreds of internal emails leaked to this newspaper reveal that clinicians at at least 18 public hospital pharmacy units across Portugal deliberately reduced concentrations or extended the prepared volumes of several expensive chemotherapy drugs between January 2024 and July 2026, affecting an estimated 7,800 patients, an independent analysis shows.
The documents — labelled internally as the 'Rationalisation Schedules' — show standard doses of drugs such as docetaxel and doxorubicin were routinely prepared at 10–25% below recommended concentrations, with batches relabelled and redistributed between oncology wards. In one record from March 2025, a procurement manager instructed five hospital pharmacies: 'Stretch current stock to 130% projected treatments; delay new orders.' The files were passed to The Plausible Post by a senior hospital pharmacist who says she blew the whistle after a patient died, citing fear of a wider cover‑up.
Tiina M. Lass, 46, a chief pharmacist who worked in two of the implicated pharmacy units and supplied the documents, told reporters in Lisbon: "We were ordered to make each vial cover more sessions. At first it was a shortcut; by summer 2025 it was standard practice. Nurses were told to 'behave like nothing changed'." Lass provided signed drawer logs, labelled vials and a copy of the email trail she said she saved to take to prosecutors.
An independent clinical review commissioned by a coalition of oncologists and patient groups, and seen by this paper, calculates the dosing changes could have reduced the delivered chemotherapy intensity by an average of 18% per treatment cycle. Using national cancer survival curves, the authors estimate the altered dosing is plausibly linked to at least 243 excess deaths and hundreds more with faster relapses — a figure the Ministry of Health calls preliminary and contested.
Dr Lenny Fritsch, an oncologist who led the review, said the pattern was striking. "This is not a batch error. It is an organised, repeated lowering of effective dose across multiple centres timed to procurement slowdowns. For some cancers, losing that intensity over several cycles materially worsens outcomes," he said. Fritsch urged an immediate audit of patient records and announced he will present the team’s findings to prosecutors on 24 September.
The Ministry of Health, which oversees the public Serviço Nacional de Saúde, said in a terse statement on Monday that it had opened an internal inquiry and notified the public prosecutor’s office after receiving an advance copy of the leaked material. Minister Ana Duarte Marques — appointed in 2024 — said three senior procurement officials had been suspended "pending investigations" and denied any deliberate policy to endanger patients. A ministry spokesperson added the government had introduced an austerity‑style 'therapeutic rationalisation' programme in late 2023 to save €48 million (about $52 million) a year amid budget pressures.
Families and patient groups reacted with fury. Simone Goncalves‑Mahe, whose sister underwent breast cancer treatment at a Porto hospital covered by the records, said: "She told me the bag looked more watery. We trusted the hospital. Now we are told to wait for a paper review while our loved ones are dead or sicker. This smells of cover‑up." Outside the ministry in Lisbon on Monday, relatives staged a noisy protest demanding immediate patient‑by‑patient reviews and compensation. Prosecutors confirmed they had opened a criminal inquiry into possible fraud, misconduct and homicide by negligence; two hospital pharmacists are under criminal interview.
The scandal threatens political fallout ahead of regional elections and raises wider questions about how austerity measures were implemented in patient‑facing services. Several private suppliers contacted by this paper reported sudden order cancellations and renegotiated contracts in 2024 and 2025; one told us a public procurement desk pushed for deferred deliveries and smaller shipments. Health unions are calling for an independent judicial commission and an immediate mandated review of all chemotherapy dosing records between 2023 and 2026. For patients and clinicians, the question is blunt and urgent: how many treatments were quietly compromised, and who authorised it?
